Topological properties of the drug targets regulated by microRNA in human protein–protein interaction network

The investigation of topological properties of proteins in protein–protein interaction network (PPIN) has great potentials to identify basic protein functions and mechanisms of action. Based on human PPIN, previous study has shown that the topological properties of drug targets are significantly distinguished from those of proteins that are not targeted by drugs (non-drug-targets). MicroRNAs (miRNAs) are known to regulate gene expression at the post-transcriptional level. To determine whether the differences in topological properties between drug targets and non-drug-targets are dominated by the proteins that are regulated by miRNA, we divided the drug targets into two sets: those are regulated by miRNA (mir-drug-targets) and those are not regulated by miRNA (non-mir-drug-targets). We compared the probability of interactions and five topological properties among the three types of proteins in human PPIN. Our results demonstrated that mir-drug-targets preferentially interact with other mir-drug-targets and tend to be hub-bottlenecks. However, there was no bias on topological properties between non-mir-drug-targets and non-drug-targets. The same topological features are observed among non-drug targets. These findings indicate that miRNA regulation has an important role in human PPIN, and may be useful in the development of novel drugs.

[1]  홀덴 데이비드윌리암,et al.  Identification of genes , 1995 .

[2]  A. E. Hirsh,et al.  Evolutionary Rate in the Protein Interaction Network , 2002, Science.

[3]  D. Bu,et al.  Topological structure analysis of the protein-protein interaction network in budding yeast. , 2003, Nucleic acids research.

[4]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[5]  M. Vidal,et al.  Interactome: gateway into systems biology. , 2005, Human molecular genetics.

[6]  R. Plasterk,et al.  MicroRNA function in animal development , 2005, FEBS letters.

[7]  E. Miska,et al.  MicroRNA functions in animal development and human disease , 2005, Development.

[8]  D. Ingber,et al.  High-Betweenness Proteins in the Yeast Protein Interaction Network , 2005, Journal of biomedicine & biotechnology.

[9]  Q. Waisfisz,et al.  Identification of genes potentially involved in disease transformation of CML , 2005, Leukemia.

[10]  H. Lehrach,et al.  A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.

[11]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. S. Deshpande,et al.  Human protein reference database—2006 update , 2005, Nucleic Acids Res..

[13]  Martin G. Everett,et al.  A Graph-theoretic perspective on centrality , 2006, Soc. Networks.

[14]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[15]  Benno Schwikowski,et al.  Graph-based methods for analysing networks in cell biology , 2006, Briefings Bioinform..

[16]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[17]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[18]  Zhaowei Zhong,et al.  Quantitative analysis on the characteristics of targets with FDA approved drugs , 2007, International journal of biological sciences.

[19]  Ole A. Andreassen,et al.  Brain Expressed microRNAs Implicated in Schizophrenia Etiology , 2007, PloS one.

[20]  R. Sharan,et al.  Network-based prediction of protein function , 2007, Molecular systems biology.

[21]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[22]  Wen-Hsiung Li,et al.  MicroRNA regulation of human protein protein interaction network. , 2007, RNA.

[23]  Mark M. Davis,et al.  miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection , 2007, Cell.

[24]  T Chaplin,et al.  MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis , 2007, Leukemia.

[25]  Sherry L. Jenkins,et al.  Network analysis of FDA approved drugs and their targets. , 2007, The Mount Sinai journal of medicine, New York.

[26]  William Loging,et al.  High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.

[27]  Molly Megraw,et al.  miRGen: a database for the study of animal microRNA genomic organization and function , 2006, Nucleic Acids Res..

[28]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[29]  G. Tzivion,et al.  Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.

[30]  Chun-Wei Hsu,et al.  Characterization of microRNA‐regulated protein‐protein interaction network , 2008, Proteomics.

[31]  C. Croce,et al.  MicroRNAs in diseases and drug response. , 2008, Current opinion in pharmacology.

[32]  F. Hirsch,et al.  EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[34]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[35]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[36]  H. McLeod,et al.  EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  A. Pivarcsi,et al.  MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. , 2008, Seminars in cancer biology.

[38]  Jean-Marc Schwartz,et al.  A global view of drug-therapy interactions , 2007, BMC pharmacology.

[39]  Ozlem Keskin,et al.  Human Cancer Protein-Protein Interaction Network: A Structural Perspective , 2009, PLoS Comput. Biol..

[40]  Wei Jiang,et al.  The analysis of the drug–targets based on the topological properties in the human protein–protein interaction network , 2009, Journal of drug targeting.

[41]  Shaojun Zhang,et al.  Functional homogeneity in microRNA target heterogeneity--a new sight into human microRNomics. , 2011, Omics : a journal of integrative biology.